<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113409</url>
  </required_header>
  <id_info>
    <org_study_id>#7456</org_study_id>
    <nct_id>NCT03113409</nct_id>
  </id_info>
  <brief_title>Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol</brief_title>
  <official_title>Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient&#xD;
      study of methods to facilitate induction and stabilization onto XR-NTX. There will be three&#xD;
      different methods of XR-NTX induction using increasing doses of oral naltrexone and&#xD;
      buprenophine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will&#xD;
      receive XR-NTX on day five together with buprenorphine, and will continue receiving&#xD;
      buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.&#xD;
&#xD;
      Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily&#xD;
      doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX&#xD;
      dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.&#xD;
&#xD;
      Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily&#xD;
      doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX&#xD;
      dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd&#xD;
      XR-NTX dose.&#xD;
&#xD;
      All participants will receive weekly therapy with a study psychiatrist. All participants will&#xD;
      receive open-label medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no funding available to continue&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who receive the second injection of XR-NTX.</measure>
    <time_frame>4 weeks after 1st injection</time_frame>
    <description>Percentage of patient who initially received the 1st injection of XR-NTX, who receive the 2nd injection</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Procedure 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Procedure 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Procedure 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine will be administered daily</description>
    <arm_group_label>Procedure 1</arm_group_label>
    <arm_group_label>Procedure 2</arm_group_label>
    <arm_group_label>Procedure 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX</description>
    <arm_group_label>Procedure 1</arm_group_label>
    <arm_group_label>Procedure 2</arm_group_label>
    <arm_group_label>Procedure 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivitrol</intervention_name>
    <description>Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.</description>
    <arm_group_label>Procedure 1</arm_group_label>
    <arm_group_label>Procedure 2</arm_group_label>
    <arm_group_label>Procedure 3</arm_group_label>
    <other_name>XR-NTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-60.&#xD;
&#xD;
          2. Meets DSM-5 criteria for current opioid use disorder (moderate-severe) of at least six&#xD;
             months duration, supported by urine toxicology OR COWS score &gt; or =6 OR Naloxone&#xD;
             Challenge.&#xD;
&#xD;
          3. Voluntarily seeking treatment for opioid dependence.&#xD;
&#xD;
          4. In otherwise good health based on complete medical history and physical examination&#xD;
             within normal ranges (AST or ALT &lt; 3 times normal). )&#xD;
&#xD;
          5. Able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Methadone maintenance treatment or regular use of illicit methadone (&gt; 30 mg per&#xD;
             week).&#xD;
&#xD;
          2. Maintenance on, or regular use of buprenorphine or other long-acting narcotic&#xD;
             agonists.&#xD;
&#xD;
          3. Pregnancy, lactation, or failure in a sexually active woman to use adequate&#xD;
             contraceptive methods.&#xD;
&#xD;
          4. Active medical illness which might make participation hazardous, such as untreated&#xD;
             hypertension, acute hepatitis with AST or ALT &gt; 3 times normal, AIDS (CD4 count under&#xD;
             200 currently or medically ill with an opportunistic infection), unstable diabetes.&#xD;
&#xD;
          5. Active psychiatric disorder which might interfere with participation or make&#xD;
             participation hazardous, including DSM-5 Schizophrenia or any psychotic disorder,&#xD;
             severe Major Depressive Disorder, or suicide risk or 1 or more suicide attempts within&#xD;
             the past year.&#xD;
&#xD;
          6. Physiologically dependent on alcohol or sedative- hypnotics with impending withdrawal.&#xD;
             Other substance use diagnoses are not exclusionary.&#xD;
&#xD;
          7. History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone,&#xD;
             clonidine, or clonazepam.&#xD;
&#xD;
          8. Chronic organic mental disorder (e.g. AIDS (CD4 count under 200 currently or medically&#xD;
             ill with an opportunistic infection) dementia).&#xD;
&#xD;
          9. History of accidental drug overdose in the last 3 years as defined as an episode of&#xD;
             opioid-induced unconsciousness or incapacitation, whether or not medical treatment was&#xD;
             sought or received.&#xD;
&#xD;
         10. Painful medical condition that requires ongoing opioid analgesia or anticipated&#xD;
             surgery necessitating opioid medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>March 6, 2021</last_update_submitted>
  <last_update_submitted_qc>March 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Adam Bisaga</investigator_full_name>
    <investigator_title>Research Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Outpatient detoxification</keyword>
  <keyword>Opioid dependence</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Vivitrol</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

